Hepatitis C immune globulin - Biotest Pharmaceuticals

Drug Profile

Hepatitis C immune globulin - Biotest Pharmaceuticals

Alternative Names: Boca HBVIg - Biotest; Civacir; HCVIG; Hepatitis C Immune Globulin Intravenous (Human) 5% - Biotest Pharmaceuticals

Latest Information Update: 09 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nabi Biopharmaceuticals
  • Developer Biotest Pharmaceuticals; Kedrion
  • Class Antivirals; Immunoglobulins
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hepatitis C
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Hepatitis C

Most Recent Events

  • 05 May 2017 Discontinued - Phase-II for Hepatitis C (Prevention of relapse) in European Union (IV) before May 2017
  • 05 May 2017 Discontinued - Phase-III for Hepatitis C (Prevention of relapse) in Canada (IV) before May 2017
  • 01 Jun 2016 Biotest Pharmaceuticals completes a phase III trial for Hepatitis C in USA (NCT01804829)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top